Table 4.
Dysregulation of lipid metabolites in the spinal cord of SOD1G86R mice, after negative ionization, and tentative identification.
| m/z | RT | HMDB | Name | Class | Fold change |
|---|---|---|---|---|---|
| 311.3 | 6.5 | HMDB02212 | Arachidic acid (20:0) | Fatty acid | 0.61 |
| 309.3 | 5.3 | HMDB02231 | Eicosenoic acid (20:1n-9) | 0.44 | |
| 337.3 | 6.6 | HMDB02068 | Erucic acid (22:1n-9) | 0.51 | |
| 305.2 | 3.4 | HMDB02925 | 8,11,14-Eicosatrienoic acid (20:3n-6) | 0.34 | |
| 305.2 | 3.7 | HMDB02925 | 8,11,14-Eicosatrienoic acid (20:3n-6) | 0.45 | |
| 331.3 | 3.9 | HMDB02226 | Adrenic acid (22:4n-6) | 0.62 | |
| 335.3 | 5.7 | HMDB61714 | Docosadienoate (22:2n-6) | 0.52 | |
| 335.3 | 5.6 | HMDB61714 | Docosadienoate (22:2n-6) | 0.53 | |
| 329.2 | 3.1 | HMDB01976 | Docosapentaenoic acid (22n-6) | 0.54 | |
| 333.3 | 4.7 | HMDB02823 | Docosatrienoic acid (22:3n-3) | 0.42 | |
| 333.3 | 4.9 | HMDB02823 | Docosatrienoic acid (22:3n-3) | 0.42 | |
| 307.3 | 4.4 | HMDB05060 | Eicosadienoic acid (20:2n-6) | 0.41 | |
| 307.3 | 4.3 | HMDB05060 | Eicosadienoic acid (20:2n-6) | 0.49 | |
| 355.3 | 3.6 | HMDB02007 | Tetracosahexaenoic acid (24:6n-12) | 0.63 | |
| 357.3 | 4.3 | HMDB06322 | Tetracosapentaenoic acid (24:5n-6) | 0.58 | |
| 359.3 | 5.1 | HMDB06246 | Tetracosatetraenoic acid (24:4n-6) | 0.57 | |
| 379.3 | 6.5 | HMDB11545 | MG(0:0/20:3n-3/0:0) | Mono, di, triglyceride | 0.61 |
| 377.3 | 5.3 | HMDB11549 | MG(0:0/20:4n-3/0:0) | 0.40 | |
| 405.3 | 6.6 | HMDB11554 | MG(0:0/22:4n-6/0:0) | 0.51 | |
| 641.5 | 11.5 | HMDB07119 | DG(16:0/22:5n-6/0:0) | 0.59 | |
| 637.5 | 10.9 | HMDB11188 | TG(12:0/12:0/12:0) | 0.46 | |
| 845.7 | 11.9 | HMDB42567 | TG(14:0/18:3n-3/20:5n-6) | 0.48 | |
| 843.7 | 11.5 | HMDB42807 | TG(14:0/18:4n-3/20:5n-3) | 0.43 | |
| 715.6 | 11.2 | HMDB47885 | TG(14:1n-5/14:1n-5/14:1n-5) | 0.55 | |
| 791.6 | 10.9 | HMDB47904 | TG(14:1n-5/14:1n-5/20:5n-3) | 0.50 | |
| 781.6 | 10.2 | HMDB43186 | TG(15:0/14:1n-5/18:4n-3) | 0.58 | |
| 833.7 | 11.6 | HMDB43190 | TG(15:0/14:1n-5/22:6n-3) | 0.48 | |
| 831.7 | 11.6 | HMDB43679 | TG(15:0/18:4n-3/18:4n-3) | 0.43 | |
| 760.6 | 9.6 | HMDB07878 | PC(14:0/20:0) | Phospholipid | 0.56 |
| 800.6 | 10.0 | HMDB07952 | PC(15:0/22:1n-5) | 0.54 | |
| 792.6 | 9.8 | HMDB07956 | PC(15:0/22:5n-6) | 0.54 | |
| 828.6 | 10.2 | HMDB07960 | PC(15:0/24:1n-9) | 0.54 | |
| 844.7 | 11.5 | HMDB07992 | PC(16:0/24:0) | 0.54 | |
| 842.7 | 10.4 | HMDB07993 | PC(16:0/24:1n-9) | 0.54 | |
| 744.6 | 10.9 | HMDB07995 | PC(16:0/P-18:0) | 0.56 | |
| 772.6 | 11.6 | HMDB08061 | PC(18:0/P-18:0) | 0.53 | |
| 884.6 | 10.3 | HMDB08616 | PC(22:2n-6/22:6n-3) | 0.59 | |
| 914.7 | 11.6 | HMDB08750 | PC(22:6n-3/24:1n-9) | 0.54 | |
| 820.6 | 10.4 | HMDB09212 | PE(18:4n-3/24:1n-9) | 0.51 | |
| 758.6 | 11.9 | HMDB09247 | PE(20:0/dm18:0) | 2.46 | |
| 719.5 | 8.5 | HMDB10571 | PG(16:0/16:1n-9) | 0.42 | |
| 777.6 | 10.3 | HMDB10602 | PG(18:0/18:0) | 0.59 | |
| 789.6 | 9.8 | ECMDB23708 | PG(18:1n-9/19:iso) | 0.53 | |
| 564.5 | 9.4 | HMDB04950 | Ceramide (d18:1n-9/18:0) | Sphingolipid | 0.52 |
| 566.5 | 10.1 | HMDB11761 | Ceramide (d18:1n-9/18:0) | 0.63 | |
| 620.6 | 10.7 | HMDB04952 | Ceramide (d18:1n-9/22:0) | 0.53 | |
| 562.5 | 9.4 | HMDB04948 | Ceramide (d18:1n-9/18:1n-9) | 0.52 | |
| 562.5 | 9.5 | HMDB04948 | Ceramide (d18:1n-9/18:1n-9) | 0.52 | |
| 618.6 | 10.7 | HMDB11775 | Ceramide(d18:1n-9/22:1n-13) | 0.50 | |
| 672.5 | 10.0 | HMDB10702 | CerP(d18:1n-9/20:0) | 0.59 | |
| 782.6 | 10.4 | HMDB04974 | Glucosylceramide (d18:1n-9/22:0) | 0.51 | |
| 886.6 | 10.9 | HMDB11592 | Lactosyceramide (d18:1n-9/18:1n-9) | 0.46 | |
| 714.6 | 10.5 | HMDB29216 | SM C16:1n-7 | 0.61 |
Given are the dysregulated metabolites identified by the Human Metabolome Database (HMDB), in the spinal cord of symptomatic SOD1G86R mice, after negative identification. m/z, mass to charge ratio; RT, retention time (min).